Lee D Gibbs1,2, Pankaj Chaudhary3, Kelsey Mansheim4, Richard J Hare5, Rebecca A Mantsch5, Jamboor K Vishwanatha3. 1. Institute for Molecular Medicine, Texas Center for Health Disparities, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76017, USA. Lee.Gibbs@med.usc.edu. 2. Keck School of Medicine of University of Southern California, 1450 Biggy Street, NRT 2516, Los Angeles, CA, 90089-9601, USA. Lee.Gibbs@med.usc.edu. 3. Institute for Molecular Medicine, Texas Center for Health Disparities, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76017, USA. 4. Department of Pathology, Brookwood Baptist Health, 1130 22nd St S #1000, Birmingham, AL, 35205, USA. 5. Department of Pathology, Medical City Fort Worth, 900 Eighth Avenue, Fort Worth, TX, 76104, USA.
Abstract
PURPOSE: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome. METHODS: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. RESULTS: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069). CONCLUSION: AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.
PURPOSE: Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBCpatients and clinical outcome. METHODS: We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study. RESULTS: In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in otherbreast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, humanepidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBCpatients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBCpatients (CISH average score = 1.1 ± 0.4069). CONCLUSION:AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.
Entities:
Keywords:
African American; Annexin A2; Biomarker; Prognosis; Triple-negative breast cancer
Authors: Meena R Sharma; Lauren Koltowski; Robert T Ownbey; George P Tuszynski; Mahesh C Sharma Journal: Exp Mol Pathol Date: 2006-04-27 Impact factor: 3.362
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: Rowan T Chlebowski; Zhao Chen; Garnet L Anderson; Thomas Rohan; Aaron Aragaki; Dorothy Lane; Nancy C Dolan; Electra D Paskett; Anne McTiernan; F Alan Hubbell; Lucile L Adams-Campbell; Ross Prentice Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Rita Nanda; L Philip Schumm; Shelly Cummings; James D Fackenthal; Lise Sveen; Foluso Ademuyiwa; Melody Cobleigh; Laura Esserman; Noralane M Lindor; Susan L Neuhausen; Olufunmilayo I Olopade Journal: JAMA Date: 2005-10-19 Impact factor: 56.272
Authors: Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Marjo de Graauw; Ine Tijdens; Mirjam B Smeets; Paul J Hensbergen; André M Deelder; Bob van de Water Journal: Mol Cell Biol Date: 2007-12-10 Impact factor: 4.272
Authors: Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 12.779
Authors: Pankaj Chaudhary; Lee D Gibbs; Sayantan Maji; Cheryl M Lewis; Sumihiro Suzuki; Jamboor K Vishwanatha Journal: Breast Cancer Res Date: 2020-01-28 Impact factor: 6.466